Acute Leukemia

Oncology·MeSH: Graft vs Host Disease

Prevalence

30.4 / 100K

Incidence

7.5 / 100K/yr

29 drugs in development·8 companies·7 clinical trials

Drug Pipeline by Phase

Phase 3(13)

Drug	Company
Asparaginase Erwinia chrysanthemi	Cosmos Health Inc. (COSM)
Blinatumomab	Cosmos Health Inc. (COSM)
Calaspargase Pegol	Cosmos Health Inc. (COSM)
Cytarabine	Cosmos Health Inc. (COSM)
Daunorubicin	Cosmos Health Inc. (COSM)
leucovorin	GH Research PLC (GHRS)
Leucovorin	Cosmos Health Inc. (COSM)
Levoleucovorin	Cosmos Health Inc. (COSM)
Levoleucovorin	Assertio Holdings, Inc. (ASRT)
Mercaptopurine	Cosmos Health Inc. (COSM)
Thioguanine	Cosmos Health Inc. (COSM)
vincristine	GH Research PLC (GHRS)
Vincristine	Cosmos Health Inc. (COSM)

Phase 2(9)

Drug	Company
CAR T-cells	ENANTA PHARMACEUTICALS INC (ENTA)
Levoleucovorin	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Levoleucovorin	Filana Therapeutics Inc. (FLNA)
revumenib	GH Research PLC (GHRS)
Therapeutic Hydrocortisone	Cosmos Health Inc. (COSM)
Therapeutic Hydrocortisone	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Venetoclax	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Venetoclax	Cosmos Health Inc. (COSM)
Venetoclax	Assertio Holdings, Inc. (ASRT)

Phase 1(4)

Drug	Company
Donor-derived Mesenchymal Stromal Cells	ENANTA PHARMACEUTICALS INC (ENTA)
Filgrastim	AbbVie Inc. (ABBV)
memory-like natural killer cells	ENANTA PHARMACEUTICALS INC (ENTA)
Revumenib	Syndax Pharmaceuticals Inc (SNDX)

Phase 2/Phase 3(2)

Drug	Company
blinatumomab	GH Research PLC (GHRS)
calaspargase pegol	GH Research PLC (GHRS)

Phase 4(1)

Drug	Company
NK Cells	ENANTA PHARMACEUTICALS INC (ENTA)

BioSniper tracks 29 drugs in development for Acute Leukemia across 8 companies.

There are 7 clinical trials targeting Acute Leukemia tracked by BioSniper.

The estimated prevalence of Acute Leukemia is approximately 30.4 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.